Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

InmunoSIGHT. Immunological and molecular characterization in liquid biopsy of lung cancer patients for immunotherapy

The main objective of the present project is the development of a tool that allows to characterize, from an immunological and molecular point of view, patients with non-small cell lung cancer. The project aims to define a molecular signature to stratify patients for immunotherapy, integrating clinical, molecular and immunological data specific to the tumor and that identifies the long survivors with these treatments, currently impossible to recognize in advance with any known parameter.


To this end, a cohort of 150 patients diagnosed with non-small cell lung cancer, stage IV, will be recruited to investigate their immune status and the relationship with survival to immunotherapy, paying special attention to those patients considered long survivors (> 2 years of global survival).

In order to successfully achieve the objectives of the project, a consortium has been set up between Atrys, the project leader, the University Hospital Puerta de Hierro Majadahonda (FIBPH) and the Leitat Technology Center

This project has been funded by the “Ministerio de Ciencia, Innovación y Universidades” within the RETOS-COLLABORATION Subprogram, Call 2017. The project is co-funded by the European Union with the aim of promoting technological development, innovation and quality research

ID: RTC-2017-6502-1

2018-2021